Save your seat

Trainers details

  • Dr. Markus Fido
  • Chief Executive Officer
  • VelaLabs GmbH

Markus has more than 20 years of experience in pharmaceutical industry, with focus in vaccines, recombinant proteins and immune therapeutics. He has profound expertise in regulatory aspects such as third party audits, authority inspections and GMP guidelines.

He has a management consulting education and holds a doctorate degree in chemistry/biochemistry from the Technical University of Graz, Austria. Besides serving as a CEO and formal Managing Director, Markus has also taken responsibilities as a Head of Regulatory Affairs within the Quality Operations team. Markus was previously Head Quality Control at Igeneon/Aphton Biopharma where he was responsible for all QC aspects of pre-clinical and clinical projects such as stability studies, specifications, method validation, and product release.

Before he was Group Leader of Immunology and Product Development at Biomin GmbH, Head Biochemical Control at Baxter AG and Head Quality Operations at Octapharma GmbH.

  • DI Rainer Fedra
  • Head Analytical Development
  • VelaLabs GmbH

Rainer started his career in the Quality Control Labs of Boehringer Ingelheim Vienna, during hisstudies of pharmaceutical biotechnology at the IMC Krems. He joined Vela laboratories in 2011. His current position is Deputy Head Laboratory, Head Assay Development. During his career at Boehringer Ingelheim and Vela, Rainer gained a profound knowledge and understanding of bioanalytical methods and became a regulatory expert utilizing the latest updates of GMP, GCP, GLP, GCLP.

  • Dr. Mahdi Adibzadeh
  • Group Head Analytical R&D and QC
  • Hoffmann-La Roche

Dr. Adibzadeh has conducted his PhD. studies at Eberhard- Karls-Universität in Tübingen. He served as a supervisor of the European Union Concerted Action on the Molecular Biology of Immunosenescence (EUCAMBIS). In 2000, he continued his post-doctoral research and studies at
Max-Planck-Institute for Biochemistry in Munich focusing at the screening of tumor suppressor genes. In 2001 he joined Migragen AG as a scientist, responsible for Immunology Group Deputy for GLP and quality control. In 2004 Dr. Adibzadeh joined F. Hoffmann-La Roche as a Senior Scientist in the department of Immunotoxicology establishment and validation of immunological test methods. From 2008 he is a Principal Scientist in the department of Quality Control establishment and validation of immunological test methods and their implementation in analytics from Phase I till end of Phase III. Currently serving as a Group Head Analytical R&D and QC Biotech Products in bioassay section.